SG10201706590VA - Modulators of 5-ht receptors and methods of use thereof - Google Patents
Modulators of 5-ht receptors and methods of use thereofInfo
- Publication number
- SG10201706590VA SG10201706590VA SG10201706590VA SG10201706590VA SG10201706590VA SG 10201706590V A SG10201706590V A SG 10201706590VA SG 10201706590V A SG10201706590V A SG 10201706590VA SG 10201706590V A SG10201706590V A SG 10201706590VA SG 10201706590V A SG10201706590V A SG 10201706590VA
- Authority
- SG
- Singapore
- Prior art keywords
- modulators
- receptors
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18056909P | 2009-05-22 | 2009-05-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201706590VA true SG10201706590VA (en) | 2017-09-28 |
Family
ID=42562780
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2014014328A SG2014014328A (en) | 2009-05-22 | 2010-05-20 | Modulators of 5-ht receptors and methods of use thereof |
SG10201706590VA SG10201706590VA (en) | 2009-05-22 | 2010-05-20 | Modulators of 5-ht receptors and methods of use thereof |
SG2011084357A SG176100A1 (en) | 2009-05-22 | 2010-05-20 | Modulators of 5-ht receptors and methods of use thereof |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2014014328A SG2014014328A (en) | 2009-05-22 | 2010-05-20 | Modulators of 5-ht receptors and methods of use thereof |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG2011084357A SG176100A1 (en) | 2009-05-22 | 2010-05-20 | Modulators of 5-ht receptors and methods of use thereof |
Country Status (18)
Country | Link |
---|---|
US (3) | US9187483B2 (en) |
EP (2) | EP2432783B1 (en) |
JP (2) | JP5791595B2 (en) |
KR (1) | KR101784674B1 (en) |
CN (2) | CN105481864A (en) |
AU (1) | AU2010249472B2 (en) |
BR (1) | BRPI1010604A2 (en) |
CA (1) | CA2761961C (en) |
ES (2) | ES2423668T3 (en) |
HK (1) | HK1168853A1 (en) |
IL (1) | IL216193A (en) |
MX (1) | MX2011012479A (en) |
NZ (2) | NZ618902A (en) |
RU (2) | RU2014147175A (en) |
SG (3) | SG2014014328A (en) |
TW (1) | TWI492947B (en) |
WO (1) | WO2010135560A1 (en) |
ZA (1) | ZA201601457B (en) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2423668T3 (en) | 2009-05-22 | 2013-09-23 | Abbvie Inc. | 5-HT receptor modulators and methods of use thereof |
WO2011116282A2 (en) | 2010-03-19 | 2011-09-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Nicotinic acetylcholine receptor agonists |
CN103002735B (en) * | 2010-05-21 | 2015-05-20 | Abbvie公司 | Modulators of 5-ht receptors and methods of use thereof |
JP6198715B2 (en) * | 2012-03-06 | 2017-09-20 | 武田薬品工業株式会社 | Tricyclic compounds |
WO2014048958A1 (en) * | 2012-09-27 | 2014-04-03 | Bayer Cropscience Ag | Process for the preparation of optionally substituted phenyl and pyridyl pyrrolidines |
US9643947B2 (en) | 2013-08-28 | 2017-05-09 | Northwestern University | 7-membered fused heterocycles and methods of their synthesis |
RU2667954C2 (en) * | 2016-03-04 | 2018-09-25 | Общество С Ограниченной Ответственностью "Валентек" | Pharmaceutical composition for treatment of functional mental disorders |
CN107311948A (en) * | 2017-06-16 | 2017-11-03 | 福州大学 | A kind of key intermediates of MI 2 and preparation method thereof |
US11560383B2 (en) * | 2018-03-05 | 2023-01-24 | Japan Science And Technology Agency | Compound and polymer compound containing the compound |
Family Cites Families (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4350814A (en) * | 1979-10-22 | 1982-09-21 | Ici Americas Inc. | Pyrrolo [3,4-c]quinoline compounds |
US4268513A (en) * | 1979-10-22 | 1981-05-19 | Ici Americas Inc. | Pyrrolo [3,4-c]quinoline compounds and pharmaceutical compositions, methods for their use and preparation |
US4440768A (en) * | 1981-01-08 | 1984-04-03 | Ici Americas Inc. | Hexahydropyrrolo[3,4-c]quinoline compounds and pharmaceutical compositions, and methods for their use |
US5049564A (en) * | 1989-11-17 | 1991-09-17 | Abbott Laboratories | 5-HT selective agents |
WO1990006927A1 (en) | 1988-12-15 | 1990-06-28 | Abbott Laboratories | 5-ht selective agents |
WO1991003467A1 (en) | 1989-08-30 | 1991-03-21 | Pfizer Inc. | Benzazabicyclic carbamates as novel cholinesterase inhibitors |
HUT71246A (en) * | 1992-08-24 | 1995-11-28 | Merrell Pharma Inc | Mercaptoacylamine-substituted benzazepine derivatives condensed with heterocycles and process for preparing them |
US5317017A (en) | 1992-09-30 | 1994-05-31 | Merck & Co., Inc. | N-biphenyl-3-amido substituted benzolactams stimulate growth hormone release |
US5597922A (en) | 1994-07-29 | 1997-01-28 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Glycine receptor antagonist pharmacophore |
WO1996038435A1 (en) | 1995-05-30 | 1996-12-05 | Abbott Laboratories | Dopamine agonists |
JPH09221475A (en) | 1996-02-13 | 1997-08-26 | Yamanouchi Pharmaceut Co Ltd | Novel oxime derivative |
US5880122A (en) * | 1996-11-01 | 1999-03-09 | American Home Products Corporation | 3-Carboxamide derivatives of 5H-pyrrolo 2,1-c! 1,4!-benzodiazepines |
US6528517B1 (en) | 1998-02-04 | 2003-03-04 | Board Of Regents, The University Of Texas System | Synthesis of quinobenzoxazine analogues with topoisomerase II and quadruplex interactions for use as antineoplastic agents |
EP1244457B1 (en) | 1999-12-29 | 2004-10-27 | Glaxo Group Limited | Use of modulators of annexin for the manufacture of a medicament for the treatment and/or prevention of arthritis and arthritic diseases |
EP1406631A4 (en) | 2001-06-13 | 2005-03-23 | Univ Michigan | Dopamine receptor ligands and therapeutic methods based thereon |
US20080146583A1 (en) | 2003-05-15 | 2008-06-19 | Pfizer Inc | Treatment of Incontinence |
AU2004259009A1 (en) | 2003-07-23 | 2005-02-03 | Exelixis, Inc. | Azepine derivatives as pharmaceutical agents |
KR100601641B1 (en) * | 2003-08-08 | 2006-07-14 | 삼성전자주식회사 | Bipyridine-based metal complex and ink composition comprising the same |
RU2266906C1 (en) | 2004-04-29 | 2005-12-27 | Общество с ограниченной ответственностью "Исследовательский Институт Химического Разнообразия" (ООО "Исследовательский Институт Химического Разнообразия") | Anellated carbamoyl azaheterocycles, methods for their preparing (variants), pharmaceutical composition, focused library |
US7572805B2 (en) * | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
US7618980B2 (en) * | 2004-07-14 | 2009-11-17 | Bristol-Myers Squibb Company | Pyrrolo(oxo)quinolines as 5HT ligands |
TW200621677A (en) | 2004-09-21 | 2006-07-01 | Astellas Pharma Inc | Cyclic amine derivative or salt thereof |
SI1833473T1 (en) | 2004-12-23 | 2010-01-29 | Arena Pharm Inc | 5ht2c receptor modulator compositions and methods of use |
ES2342110T3 (en) * | 2005-06-17 | 2010-07-01 | Janssen Pharmaceutica Nv | NEW TETRACICLIC TETRAHYDROFURAN DERIVATIVES CONTAINING A SIDE CHAIN OF CYCLINE AMINE. |
JP2009501176A (en) * | 2005-07-12 | 2009-01-15 | アボット ゲーエムベーハー ウント カンパニー カーゲー | Pyridazine compounds as glycogen synthase kinase 3 inhibitors |
US20070022527A1 (en) * | 2005-07-28 | 2007-02-01 | Jessica Russo | Foot scrubbing and massaging assembly |
NZ566022A (en) * | 2005-07-28 | 2011-04-29 | Vertex Pharma | Caspase inhibitor prodrugs |
GB0517292D0 (en) | 2005-08-24 | 2005-10-05 | Univ Dundee | Cell migration modulating compounds |
JP5073664B2 (en) * | 2005-08-31 | 2012-11-14 | エフ.ホフマン−ラ ロシュ アーゲー | Pyrazolone derivatives as 11-βHSD1 inhibitors |
US8088759B2 (en) | 2005-11-01 | 2012-01-03 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones with therapeutic properties |
US20070135387A1 (en) | 2005-12-08 | 2007-06-14 | Michaelides Michael R | Inhibitors of protein kinases |
JP4873614B2 (en) * | 2006-01-16 | 2012-02-08 | 国立大学法人 東京大学 | Potassium channel opener |
EP1998782A2 (en) | 2006-03-24 | 2008-12-10 | Wyeth a Corporation of the State of Delaware | Methods for modulating bladder function |
EP1998781A2 (en) | 2006-03-24 | 2008-12-10 | Wyeth a Corporation of the State of Delaware | Treatment of pain |
WO2008082887A2 (en) * | 2006-12-28 | 2008-07-10 | Abbott Laboratories | Inhibitors of poly(adp-ribose)polymerase |
TW200924752A (en) | 2007-09-17 | 2009-06-16 | Organon Nv | Tricyclic heterocyclic derivatives |
WO2009120733A1 (en) | 2008-03-27 | 2009-10-01 | Bristol-Myers Squibb Company | Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors |
GB0817576D0 (en) | 2008-09-25 | 2008-11-05 | Lectus Therapeutics Ltd | Calcium ion channel modulators & uses thereof |
ES2568262T3 (en) * | 2009-04-23 | 2016-04-28 | Abbvie Inc. | 5-HT receptor modulators and their methods of use |
ES2423668T3 (en) | 2009-05-22 | 2013-09-23 | Abbvie Inc. | 5-HT receptor modulators and methods of use thereof |
-
2010
- 2010-05-20 ES ES10720502T patent/ES2423668T3/en active Active
- 2010-05-20 MX MX2011012479A patent/MX2011012479A/en active IP Right Grant
- 2010-05-20 NZ NZ618902A patent/NZ618902A/en not_active IP Right Cessation
- 2010-05-20 SG SG2014014328A patent/SG2014014328A/en unknown
- 2010-05-20 EP EP10720502.3A patent/EP2432783B1/en not_active Not-in-force
- 2010-05-20 SG SG10201706590VA patent/SG10201706590VA/en unknown
- 2010-05-20 NZ NZ596827A patent/NZ596827A/en not_active IP Right Cessation
- 2010-05-20 EP EP13161013.1A patent/EP2641907B1/en not_active Not-in-force
- 2010-05-20 JP JP2012512042A patent/JP5791595B2/en not_active Expired - Fee Related
- 2010-05-20 ES ES13161013.1T patent/ES2535490T3/en active Active
- 2010-05-20 CA CA2761961A patent/CA2761961C/en not_active Expired - Fee Related
- 2010-05-20 RU RU2014147175/04A patent/RU2014147175A/en not_active Application Discontinuation
- 2010-05-20 RU RU2011152312/04A patent/RU2542103C2/en not_active IP Right Cessation
- 2010-05-20 CN CN201510919990.3A patent/CN105481864A/en active Pending
- 2010-05-20 BR BRPI1010604A patent/BRPI1010604A2/en not_active Application Discontinuation
- 2010-05-20 CN CN201080033293.3A patent/CN102712643B/en not_active Expired - Fee Related
- 2010-05-20 SG SG2011084357A patent/SG176100A1/en unknown
- 2010-05-20 KR KR1020117030649A patent/KR101784674B1/en active IP Right Grant
- 2010-05-20 WO PCT/US2010/035626 patent/WO2010135560A1/en active Application Filing
- 2010-05-20 AU AU2010249472A patent/AU2010249472B2/en not_active Ceased
- 2010-05-21 US US12/784,624 patent/US9187483B2/en not_active Expired - Fee Related
- 2010-05-21 TW TW099116465A patent/TWI492947B/en not_active IP Right Cessation
-
2011
- 2011-11-07 IL IL216193A patent/IL216193A/en not_active IP Right Cessation
-
2012
- 2012-09-28 HK HK12109595.6A patent/HK1168853A1/en not_active IP Right Cessation
-
2015
- 2015-08-03 JP JP2015153125A patent/JP6117872B2/en active Active
- 2015-10-19 US US14/887,171 patent/US9879033B2/en active Active
-
2016
- 2016-03-03 ZA ZA2016/01457A patent/ZA201601457B/en unknown
-
2018
- 2018-01-29 US US15/882,008 patent/US20180346484A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL247595A0 (en) | Novel modulators and methods of use | |
ZA201601457B (en) | Modulators of 5-ht receptors and methods of use thereof | |
ZA201102674B (en) | Spiro-tetracyclic ring compounds as betasecretase modulators and methods of use | |
EP2427479A4 (en) | Antibodies and methods of use thereof | |
SG10201601792UA (en) | Novel modulators and methods of use | |
IL215402A0 (en) | Anti-fcrh5 antibodies and immunoconjugates and methods of use | |
ZA201107128B (en) | Anti-fcrh5 antibodies and immunoconjugates and methods of use | |
EP2624790A4 (en) | Intervertebral device and methods of use | |
EP2411024A4 (en) | Factor viii variants and methods of use | |
EP2571353A4 (en) | Modulators of 5-ht receptors and methods of use thereof | |
SI2373691T1 (en) | Anti-fxi antibodies and methods of use | |
IL236830A0 (en) | Diazahomoadamantane derivatives and methods of use thereof | |
IL215795A0 (en) | Anti-il-17f antibodies and methods of use thereof | |
IL208939A0 (en) | 5-ht3 receptor modulators, methods of making, and use thereof | |
HK1149933A1 (en) | Diazacarbazoles and methods of use | |
IL211623A0 (en) | Anti-notch2 antibodies and methods of use | |
EP2464227A4 (en) | Compounds and methods of use thereof | |
IL209548A0 (en) | Diazacarbazoles and methods of use | |
EP2776437A4 (en) | Modulators of opioid receptors and methods of use thereof | |
EP2651412A4 (en) | Androgen receptor inhibitors and methods of use thereof | |
EP2560973A4 (en) | Modulators of 5-ht receptors and methods of use thereof | |
IL217297A0 (en) | 5-ht3 receptor modulators, methods of making, and use thereof | |
EP2381950A4 (en) | Compositions and methods of use | |
EP2421862A4 (en) | Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor | |
HK1174620A1 (en) | Indazolyl-substituted dihydroisoxa-zolopyridines and methods of use thereof |